Life Sciences Partners, Ysios Capital, Kurma Partners and VI Partners participated in a €10.35m series-D funding round for Xeltis.
LSP, which led the round, is currently investing from its Life Sciences Partners VI fund, which closed on €410m in November 2018.
The fresh capital will finance the company's vascular and valve trial programmes.
The company's technology is currently in clinical trials in the EU, Asia and in the US, with 28 patients receiving Xeltis devices to date.
In 2012, Xeltis merged with Qtis/E.
LSP and Kurma led a €27m series-A for Xeltis in December 2014. VI Partners was already a shareholder at this stage and also took part in the financing.
All three investors also backed the company's €3m series-B in December 2015.
Ysios joined a consortium of investors to provide a €45m series-C funding round for the company in 2017. The round was led by an anonymous strategic investor and also included contributions from LSP, Kurma Partners and VI Partners.
Xeltis is a clinical-stage medical device company that has built a polymer-based technology designed to enable natural restoration of cardiovascular function. Founded in 2006 as a University of Zurich spinout, the company is headquartered in Zurich and employs around 40 people, according to LinkedIn.
Life Sciences Partners – Clemens van Blitterswijk (partner).
Xeltis – Eliane Schutte (CEO).
Company plans to open offices in New York and Los Angeles, and launch a new SaaS product
Bridges drew equity from its Evergreen fund, which held a final close on £50m in July 2018
Fund targets European companies operating in the consumer, industrial and healthcare services sectors
GP launched a small-cap strategy in Q3 to back companies of the size of ID Systemes